Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.
Company Details
- Employees
- 11
- Address
- 345 Park Ave S, New York,new York 10010,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.aperturagtx.com
- Keywords
- New York.
- HQ
- New York, New York
Apertura Gene Therapy Questions
Apertura Gene Therapy's website is http://www.aperturagtx.com
Apertura Gene Therapy's LinkedIn profile is https://www.linkedin.com/company/apertura-gene-therapy
Apertura Gene Therapy has
11 employees.
View email and phone details for 11
employees at Apertura Gene Therapy.
Apertura Gene Therapy's industry is
Biotechnology Research
Apertura Gene Therapy's top competitors are
Pheast Therapeutics,
Lexeo Therapeutics,
Voyager Therapeutics, Inc.,
Genezen,
Spark Therapeutics, Inc.,
Prevail Therapeutics,
Deerfield Management,
Taysha Gene Therapies,
Jaguar Gene Therapy,
Bitterroot Bio.
Apertura Gene Therapy's categories are Biotechnology Research
